http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2739411-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43f900053aec923eb38a8468e305af43 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-49 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 |
| filingDate | 2020-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3110c0027657e44522e162956cacc588 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d1230bacb9ceee341a379354fd1f9de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c71c32490ccf4b9b360a6b3a40e0f1f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17cf08dbb645653d84ac5337401a14d1 |
| publicationDate | 2020-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2739411-C1 |
| titleOfInvention | Diagnostic method of atypical cases of familial mediterranean fever |
| abstract | FIELD: medicine.SUBSTANCE: invention refers to rheumatology and can be used for diagnosing atypical cases of periodical fever (FMF) in healthcare facilities. Diagnostics of FMF in atypical course with no effect of colchicine intake in hospital includes subcutaneous injection of anakinra interleukin-1 inhibitor by a medical worker in the absence of contraindications immediately after development of an attack suspicious on atypical FMF. That is ensured by the daily thermometry every 2 hours with sleep interruption and daily blood sampling at the admission to hospital in response to an attack with the determination of the serum CRP. At increase of temperature ≥38°C, development of pain in abdominal and/or thoracic cavity with VAS pain ≥60 mm, higher serum CRP level ≥5 mg/l, the health worker makes anakinra 100 mg subcutaneously in the absence of contraindications. Thermometry, VAS pain assessment and repeated determination of serum CRP level are performed 12 hours after the injection. Reducing pain intensity by VAS <30 mm, low temperature ≤37.4°C, blood serum CRP <5 mg/l not later than 12 hours after the injection is evaluated as a positive effect. If observing this effect and no undesirable medicinal reactions, the anakinra is injected 100 mg subcutaneously every 24 hours for 14 days with underlying thermometry of 6 t/day and serum blood plasma CRP daily. If observing no recurrences of anakinra for 14 days in the form of developing pain in the abdominal and/or thoracic cavity by VAS >30 mm, temperature >37.4°C, serum CRP >5 mg/l, the diagnostic test for atypical FMF is considered to be positive.EFFECT: method provides accurate and early criterial diagnostics with simultaneous effective treatment of the patients of the given group in an adequate dose, with no side effects.1 cl, 1 dwg, 2 ex |
| priorityDate | 2020-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.